Holen Sie sich die Stockscreener-App
179.77
0.75%
1.33
Handel nachbörslich:
179.77
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$178.44
Offen:
$178.94
24-Stunden-Volumen:
810.20K
Relative Volume:
0.77
Marktkapitalisierung:
$20.10B
Einnahmen:
$9.54B
Nettoeinkommen (Verlust:
$841.00M
KGV:
24.16
EPS:
7.44
Netto-Cashflow:
$1.02B
1W Leistung:
+1.59%
1M Leistung:
+8.02%
6M Leistung:
+6.52%
1J Leistung:
+20.09%
1-Tages-Spanne:
$177.27
$180.37
1-Wochen-Bereich:
$175.56
$180.37
52-Wochen-Spanne:
$146.17
$182.38
Quest Diagnostics Inc Stock (DGX) Company Profile
Firmenname
Quest Diagnostics Inc
Sektor
Branche
Telefon
(973) 520-2700
Adresse
500 PLAZA DRIVE, SECAUCUS
Vergleichen Sie DGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
179.77 | 19.95B | 9.54B | 841.00M | 1.02B | 7.44 |
|
TMO
Thermo Fisher Scientific Inc
|
489.01 | 183.16B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
210.93 | 150.53B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
650.84 | 52.32B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
119.20 | 33.77B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
191.09 | 32.20B | 15.50B | 1.33B | 2.16B | 7.34 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-01-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | Jefferies | Buy |
| 2024-10-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Fortgesetzt | Evercore ISI | In-line |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-02-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-29 | Eingeleitet | Piper Sandler | Neutral |
| 2023-05-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-23 | Eingeleitet | Evercore ISI | In-line |
| 2022-11-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-23 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-02 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-28 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-03-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Hochstufung | Argus | Hold → Buy |
| 2020-07-29 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-09 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-04-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2019-04-02 | Hochstufung | Jefferies | Hold → Buy |
| 2019-03-18 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-01-31 | Herabstufung | Argus | Buy → Hold |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2019-01-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Quest Diagnostics Inc Aktie (DGX) Neueste Nachrichten
Quest Diagnostics to Speak at the Baird 2025 Global Healthcare C - GuruFocus
Quest Diagnostics To Speak At The Baird 2025 Global Healthcare Conference - Barchart.com
Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock - Yahoo Finance
Quest Diagnostics Declares Quarterly Cash Dividend, Payable on October 20, 2025 - MarketScreener
Medical Testing Giant Quest Diagnostics Maintains $0.80 Quarterly Dividend Payout - Stock Titan
Published on: 2025-08-12 17:41:01 - sundaytimes.kr
Quest Diagnostics acquires Fresenius lab assets for dialysis - NJBIZ
Major Clinical Trials Launch: New Blood Test Could Transform Post-Surgery Cancer Detection - Stock Titan
Quest Diagnostics (DGX) Insider Plans $968k Share Sale – Form 144 | SBS SEC FilingForm 6-K - Stock Titan
What to Expect From Quest Diagnostics' Q2 2025 Earnings Report - MSN
Quest Diagnostics Completes Acquisition of Clinical Testing Assets from Fresenius Medical Care - MarketScreener
Quest Diagnostics Takes Over Fresenius Labs, Set to Serve 200,000 Dialysis Patients Annually - Stock Titan
How many analysts rate Quest Diagnostics Incorporated as a “Buy”Get exclusive market analysis for investors - Jammu Links News
What is Quest Diagnostics Incorporated company’s growth strategyTremendous gains - Jammu Links News
Quest Diagnostics Incorporated Stock Analysis and ForecastFree Predictions - Jammu Links News
What are the technical indicators suggesting about Quest Diagnostics IncorporatedMaximize your returns with expert insights - Jammu Links News
What catalysts could drive Quest Diagnostics Incorporated stock higher in 2025Turbocharged investment results - Jammu Links News
Quest Diagnostics Raises 2025 Guidance - AOL.com
Quest Diagnostics Insider Selling: A Signal of Caution or a Strategic Move Amid Strong Fundamentals? - AInvest
Published on: 2025-08-01 19:05:55 - metal.it
Is Quest Diagnostics Incorporated stock overvalued or undervaluedFinancial News Updates Backed By Experts - Jammu Links News
Earnings visualization tools for Quest Diagnostics IncorporatedVerified Signal From Chart Patterns Detected - metal.it
Drug Abuse Testing Market Forecast and Company Analysis - GlobeNewswire
Drug Abuse Testing Market Forecast and Company Analysis Report 2025-2033 Featuring Danaher, LabCorp, Abbott, Quest Diagnostics, Thermo Fisher Scientific, F. Hoffmann-La Roche, Bio-Rad, Medtronic - Yahoo Finance
Quest Diagnostics Breakthrough: New Long-Read DNA Test Revolutionizes Ataxia Movement Disorder Detection - Stock Titan
North America Autoimmune Disease Diagnostics Market Report - GlobeNewswire
North America Autoimmune Disease Diagnostics Market Report 2025-2033 Featuring Bio-Rad, Abbott, Roche, Quest Diagnostics, Thermo Fisher Scientific, BioMerieux, Myriad Genetics, Siemens Healthineers - Yahoo Finance
What makes Quest Diagnostics Incorporated stock price move sharplyTrade Setups With Clear Risk Limits Highlighted - metal.it
Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term - sharewise.com
What is the risk reward ratio of investing in Quest Diagnostics Incorporated stockInvest smarter with real-time trading alerts - jammulinksnews.com
Why is Quest Diagnostics Incorporated stock attracting strong analyst attentionMarket-beating performance - Jammu Links News
Published on: 2025-07-28 06:28:08 - jammulinksnews.com
Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Quest Diagnostics (NYSE:DGX) Stock Price - MarketBeat
What analysts say about Quest Diagnostics Incorporated stockDynamic growth stocks - PrintWeekIndia
How high can Quest Diagnostics Incorporated stock price go in 2025High-performance investment picks - jammulinksnews.com
Quest and CVS test co-location strategy in Rhode Island - The Business Journals
Quest Diagnostics Trading Volume Drops 31.43% to $364 Million Ranking 317th Despite Stock Price Rise - AInvest
Options Corner: Quest Diagnostics' Post-Earnings Digestion Drama Opens A Science-Backed Opportunity - inkl
Quest Diagnostics’ revenue up 15.2% to USD 2.76B in Q2 2025 - Medical Buyer
Barclays Reaffirms Their Hold Rating on Quest Diagnostics (DGX) - The Globe and Mail
Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight - GuruFocus
Quest Diagnostics Incorporated's (NYSE:DGX) Shares May Have Run Too Fast Too Soon - 富途牛牛
Quest Diagnostics (DGX) Price Target Raised by UBS, Rating Maint - GuruFocus
Quest Diagnostics Lifts Outlook As Testing Demand Grows - Finimize
U.S. DTC Wellness Testing Market Forecast to 2030: A $1.91 - GlobeNewswire
Quest Diagnostics (DGX) Price Target Raised by Deutsche Bank Ana - GuruFocus
Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025 - ADVFN Brasil
Quest Diagnostics Incorporated (NYSE:DGX) Q2 2025 Earnings Call Transcript - Insider Monkey
Quest Diagnostics (DGX) Price Target Raised by Deutsche Bank | D - GuruFocus
Is Quest Diagnostics Incorporated a good long term investmentConsistently exceptional gains - Autocar Professional
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MSN
Finanzdaten der Quest Diagnostics Inc-Aktie (DGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.89%
0.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):